ArticleOncoTargets and therapy2019
Prevalence And Clinical Significance Of Oncogenic
Article in OncoTargets and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 10 citations in OpenAlex.
- Testicular lymphoma of 63 patients: a Chinese retrospective, real-world study.Frontiers in oncology · 2025Article
- Targeting macrophagic SHP2 for ameliorating osteoarthritisActa pharmaceutica Sinica. B · 2022Article
- MYD88Therapeutic advances in hematology · 2022Review
- Testicular Diffuse Large B-Cell Lymphoma-Clinical, Molecular, and Immunological Features.Cancers · 2021Review
- Primary Testicular Lymphoma with Central Nervous System Relapse Was Successfully Treated by a Chemo-Free Regimen: A Case Report and Literature Review.Cancer management and research · 2021Article
- Genomic Mutation Profile of Primary Gastrointestinal Diffuse Large B-Cell Lymphoma.Frontiers in oncology · 2021Article
- Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical Practice.Cancers · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIn this study, we investigated the prevalence of PATIENTS AND
methodsWe examined the mutational status of
resultsImmunophenotypically, MYD88 protein staining was positive in 26/30 (86.67%) cases, and 23/30 (76.7%) cases tested positive for p65 in the nucleus. Genetically,
conclusionOur results suggest that
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.